“For patients with neovascular age-related macular degeneration (nAMD), a major cause of visual impairment worldwide,[1] the advent of anti–vascular endothelial growth factor (VEGF) intravitreal injections has been an undeniable breakthrough. Anti-VEGF therapy allows for greater control of the exudative process, which can dramatically improve outcomes compared with observation alone.” “Achieving and maintaining a dry macula in the ongoing, long-term management of patients with nAMD in order to optimize global outcomes from this blinding disease should remain a priority.”
Preclinical Ophthalmic Contract Research